Limits...
Formulation and evaluation of galantamine gel as drug reservoir in transdermal patch delivery system.

Fong Yen W, Basri M, Ahmad M, Ismail M - ScientificWorldJournal (2015)

Bottom Line: Transdermal delivery of galantamine hydrobromide could avoid these unwanted side effects.The gel also showed high drug content uniformity.Hence, this formulation can be further used in the preparation of transdermal patch drug delivery system.

View Article: PubMed Central - PubMed

Affiliation: Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, 43300 Serdang, Selangor, Malaysia.

ABSTRACT
Galantamine hydrobromide is formulated in tablets and capsules prescribed through oral delivery for the treatment of Alzheimer's disease. However, oral delivery of drugs can cause severe side effects such as nausea, vomiting, and gastrointestinal disturbance. Transdermal delivery of galantamine hydrobromide could avoid these unwanted side effects. In this work, galantamine hydrobromide was formulated in gel drug reservoir which was then fabricated in the transdermal patch. The in vitro drug release studies revealed that the drug release from the donor chamber to receptor chamber of Franz diffusion cell was affected by the amount of polymer, amount of neutralizer, amount of drug, types of permeation enhancer, and amount of permeation enhancer. Visual observations of the gels showed that all formulated gels are translucent, homogeneous, smooth, and stable. These gels have pH in the suitable range for skin. The gel also showed high drug content uniformity. Hence, this formulation can be further used in the preparation of transdermal patch drug delivery system.

No MeSH data available.


Related in: MedlinePlus

Drug release profile of gel drug reservoirs with different triethanolamine percentage (mean ± S.D.; n = 3).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4374332&req=5

fig2: Drug release profile of gel drug reservoirs with different triethanolamine percentage (mean ± S.D.; n = 3).

Mentions: Figure 2 and Table 2 show the effect of the amount of triethanolamine (1.00%, 3.00%, and 5.00% w/w) on the percentage of drug release. When the amount of triethanolamine was increased, the percentage of drug release was reduced. Triethanolamine (1.00% w/w) in the gel caused higher drug release compared to when there was 5.00% w/w of triethanolamine in the gel. The reason could be due to higher amount of triethanolamine causing more viscous and more complex gel formation compared to lower amount of triethanolamine. Thus, the drug molecules are more difficult to be released from the gel [15].


Formulation and evaluation of galantamine gel as drug reservoir in transdermal patch delivery system.

Fong Yen W, Basri M, Ahmad M, Ismail M - ScientificWorldJournal (2015)

Drug release profile of gel drug reservoirs with different triethanolamine percentage (mean ± S.D.; n = 3).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4374332&req=5

fig2: Drug release profile of gel drug reservoirs with different triethanolamine percentage (mean ± S.D.; n = 3).
Mentions: Figure 2 and Table 2 show the effect of the amount of triethanolamine (1.00%, 3.00%, and 5.00% w/w) on the percentage of drug release. When the amount of triethanolamine was increased, the percentage of drug release was reduced. Triethanolamine (1.00% w/w) in the gel caused higher drug release compared to when there was 5.00% w/w of triethanolamine in the gel. The reason could be due to higher amount of triethanolamine causing more viscous and more complex gel formation compared to lower amount of triethanolamine. Thus, the drug molecules are more difficult to be released from the gel [15].

Bottom Line: Transdermal delivery of galantamine hydrobromide could avoid these unwanted side effects.The gel also showed high drug content uniformity.Hence, this formulation can be further used in the preparation of transdermal patch drug delivery system.

View Article: PubMed Central - PubMed

Affiliation: Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, 43300 Serdang, Selangor, Malaysia.

ABSTRACT
Galantamine hydrobromide is formulated in tablets and capsules prescribed through oral delivery for the treatment of Alzheimer's disease. However, oral delivery of drugs can cause severe side effects such as nausea, vomiting, and gastrointestinal disturbance. Transdermal delivery of galantamine hydrobromide could avoid these unwanted side effects. In this work, galantamine hydrobromide was formulated in gel drug reservoir which was then fabricated in the transdermal patch. The in vitro drug release studies revealed that the drug release from the donor chamber to receptor chamber of Franz diffusion cell was affected by the amount of polymer, amount of neutralizer, amount of drug, types of permeation enhancer, and amount of permeation enhancer. Visual observations of the gels showed that all formulated gels are translucent, homogeneous, smooth, and stable. These gels have pH in the suitable range for skin. The gel also showed high drug content uniformity. Hence, this formulation can be further used in the preparation of transdermal patch drug delivery system.

No MeSH data available.


Related in: MedlinePlus